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RIG-I is a cytosolic sensor of viral RNA that plays
crucial roles in the induction of type I interferons.
The C-terminal domain (CTD) of RIG-I is responsible
for the recognition of viral RNA with 50 triphosphate
(ppp). However, themechanism of viral RNA recogni-
tion by RIG-I is still not fully understood. Here, we
show that RIG-I CTD binds 50 ppp dsRNA or ssRNA,
as well as blunt-ended dsRNA, and exhibits the
highest affinity for 50 ppp dsRNA. Crystal structures
of RIG-I CTD bound to 50 ppp dsRNA with GC- and
AU-rich sequences revealed that RIG-I recognizes
the termini of the dsRNA and interacts with the 50 ppp
through extensive electrostatic interactions. Muta-
genesis and RNA-binding studies demonstrated
that similar binding surfaces are involved in the
recognition of different forms of RNA. Mutations of
key residues at the RNA-binding surface affected
RIG-I signaling in cells.
INTRODUCTION
Viral pathogens can infect hosts from bacteria to mammals.
To combat viral infection, highly sophisticated immune systems
have been developed in vertebrates to sense viral infection and
initiate antiviral responses. In addition to the adaptive immune
responses mediated by B cells and T cells, the innate immune
system maintains several families of pattern recognition recep-
tors (PRRs) that recognize molecular motifs of viral pathogens
and launch quick responses toward infection (Janeway and
Medzhitov, 2002; Pichlmair and Reis e Sousa, 2007). Two major
families of PRRs, Toll-like receptors (TLRs) and RIG-I–like recep-
tors (RLRs), play key roles in innate immune responses toward
viral infection (Akira et al., 2006). TLR3, TLR7, and TLR8 sense
viral RNA in the endosomes following phagocytosis of the patho-
gens (Kawai and Akira, 2008; Thompson and Locarnini, 2007).
RLRs RIG-I and MDA5 detect viral RNA from replicating viruses
in the cytoplasm (Pichlmair and Reis e Sousa, 2007; Yoneyama1032 Structure 18, 1032–1043, August 11, 2010 ª2010 Elsevier Ltd Aand Fujita, 2009). LGP2, a homolog of RIG-I and MDA5 lacking
the N-terminal caspase recruitment domains, regulates the
signaling of the RLRs (Rothenfusser et al., 2005; Satoh et al.,
2010; Venkataraman et al., 2007). Stimulation of the RLRs by viral
RNA induces the secretion of type I interferons (IFN-a and -b) and
other proinflammatory cytokines, conferring antiviral activity to
the host cells and activating acquired immune responses (Palm
and Medzhitov, 2009; Pichlmair and Reis e Sousa, 2007; Stetson
and Medzhitov, 2006; Yoneyama and Fujita, 2009).
RIG-I and MDA5 respond to distinct but overlapping sets of
viruses, suggesting that they recognize different forms or
structures of viral RNA (Kato et al., 2006; Takeuchi and Akira,
2009). The 50 triphosphate (ppp) group was initially identified as
a key structural feature of viral RNA that was sensed by RIG-I,
and it was suggested that 50 ppp ssRNA is the primary ligand
of RIG-I (Hornung et al., 2006; Pichlmair et al., 2006; Schlee
et al., 2009a). However, recent studies demonstrated that
dsRNA with 50 ppp are potent activators of RIG-I (Schlee et al.,
2009b; Schmidt et al., 2009). In addition, several other studies
demonstrated that synthetic dsRNA or short dsRNA mimetics
derived from RNase digestion of poly I:C can also activate
RIG-I (Kato et al., 2008; Takahasi et al., 2008, Ranjith-Kumar
et al., 2009). The crystal structure of human LGP2 C-terminal
domain (CTD) bound to dsRNA showed that the termini of
dsRNA are recognized by LGP2 (Li et al., 2009b). Consistent
with this finding, blunt-ended dsRNA rather than dsRNA with 50
or 30 overhangs binds and stimulates the activation of RIG-I
(Li et al., 2009b; Marques et al., 2006). Although blunt-ended
dsRNA with 50 ppp potently stimulates the activation of RIG-I,
ppp dsRNA with 50 overhangs does not stimulate the activation
of RIG-I effectively (Schlee et al., 2009b). Because different
forms of RNA, cell lines, and assays were used in these studies,
questions remain about the structural features of viral RNA
recognized by RIG-I. Recent studies by Rehwinkel et al. (2010)
demonstrated that the genomic RNA of influenza A virus and
Sendai virus are the physiological agonists of RIG-I. It was sug-
gested that the panhandle structure formed by the 50 and 30 ends
of the viral RNA is likely a structural feature recognized by RIG-I
(Fujita, 2009; Rehwinkel et al., 2010; Schlee et al., 2009b).
Limited proteolysis of RIG-I bound to dsRNA revealed that its
CTD (residues 792–925) is responsible for RNA bindingll rights reserved
Figure 1. RIG-I CTD Binds RNA with or
Without a 50 Triphosphate (ppp)
(A) Binding study of RIG-I CTD with a 14-bp
GC-rich 50 ppp dsRNA by gel filtration
chromatography. RIG-I CTD is shown by the black
chromatogram. The RNA is shown by the red chro-
matogram. The mixture of the protein and the RNA
is shown by the green chromatogram. Elution
volumes of four protein standards are shown
above the chromatograms.
(B) Stoichiometry between RIG-I CTD and the
14-bp GC-rich 50 ppp dsRNA in a purified protein
RNA complex determined by sedimentation
velocity (inset) and equilibrium. The experimental
molecular weight values from velocity (38 kDa)
and equilibrium (37,339 Da) data were consistent
only with the formation of a 2:1 complex.
(C) Binding study of RIG-I CTD with a 13-nt 50 ppp
ssRNA by gel filtration chromatography.
(D) Binding study of RIG-I CTD with a 14-bp blunt-
ended dsRNA without a 50 ppp.
Structure
Structure of RIG-I CTD Bound to dsRNA(Takahasi et al., 2008). Structures of the CTDs of RIG-I, LGP2,
and MDA5 have been determined recently, revealing a novel
and conserved RNA-binding domain structure (Cui et al., 2008;
Li et al., 2009a; Pippig et al., 2009; Takahasi et al., 2009; Taka-
hasi et al., 2008). The structure of LGP2 CTD bound to dsRNA
showed that the RNA binding surface is located on a positively
charged surface made up of strands b5 to b8 and loop 5–6
(Li et al., 2009b). NMR titrations of RIG-I and MDA5 CTD showed
that similar binding surfaces are involved in RNA binding by RIG-I
and MDA5 (Li et al., 2009a; Takahasi et al., 2009; Takahasi et al.,
2008). Mutagenesis of several positively charged residues on
this surface disrupted RNA binding and signaling by RIG-I
(Cui et al., 2008; Takahasi et al., 2008). On the basis of the results
from these studies, the triphosphate-binding site of RIG-I was
predicted to be located at a large positively charged surface
around residues Lys858 and Lys861 (Cui et al., 2008; Takahasi
et al., 2008). However, how RIG-I recognizes the 50 ppp of viral
RNA remains to be established.
To elucidate the structural basis of 50 ppp dsRNA recognition
by RIG-I, we expressed the CTD of human RIG-I, conducted
extensive binding studies using RNA with different structures,
and determined the crystal structures of RIG-I CTD bound to
a 14-bp GC-rich and a 12-bp AU-rich dsRNA. The structures
revealed that RIG-I CTD recognizes the termini of dsRNA and
interacts with the 50 ppp through extensive electrostatic interac-
tions. Mutagenesis of key residues at the binding surface
affected RNA binding and signaling by RIG-I.
RESULTS
RIG-I CTD Binds 50 ppp dsRNA with High Affinity
Understanding of RIG-I structure and function requires the
elucidation of the chemical basis for viral RNA recognition byStructure 18, 1032–1043, August 11, 2010 ªRIG-I. We have expressed and purified
human RIG-I CTD and characterized its
ligand-binding properties with various
forms of RNA.First, we studied the RNA binding of RIG-I CTD by gel filtration
chromatography. A 14-bp GC-rich dsRNA, a 12-bp AU-rich
dsRNA, and a 13-nucleotide (nt) ssRNA were synthesized by
in vitro transcription using T7 RNA polymerase (see Table S1
available online). We found that the 14-bp dsRNA with 50 ppp
binds RIG-I CTD and forms a stable complex (Figure 1A). Analyt-
ical ultracentrifugation (AUC) sedimentation velocity and equilib-
rium analyses of purified RIG-I CTD bound to the 14 GC 50 ppp
dsRNA demonstrated that the stoichiometry between the protein
and the dsRNA is 2:1 (Figure 1B). The 12-bp AU-rich dsRNA also
binds RIG-I CTD and forms a complex of 2:1 stoichiometry
(Figure S1), indicating that RIG-I has no preference for specific
bases within the RNA. Surprisingly, the 13-nt ssRNA with 50
ppp also binds RIG-I CTD (Figure 1C). In addition, we found
a blunt-ended dsRNA, with the same sequence as the 14-bp
GC-rich 50 ppp dsRNA but lacking the 50 ppp, also binds RIG-I
CTD and forms a stable complex with a stoichiometry of 2:1
(Figure 1D).
Second, we tested whether the 50 or 30 end overhanging
regions of 50 ppp dsRNA affect RNA binding to RIG-I CTD.
We found that ppp dsRNA with either 30 or 50 overhanging nucle-
otides retained binding to RIG-I CTD (Table S1 and Figure S1).
However, treatment of these dsRNA with shrimp alkaline phos-
phatase (SAP) that removes the 50 ppp groups dramatically
reduced their binding with RIG-I CTD (Figure S1), demonstrating
that the 50 ppp increases the affinity of the dsRNA for RIG-I.
Consistent with this observation, treatment of the12-bp 50 ppp
dsRNA without 30 or 50 overhangs using SAP also reduced its
binding for RIG-I CTD (Figure S1).
The affinity and kinetic properties of ligand binding to immu-
noreceptors determine the strength and duration of the signals
initiated by these receptors. To determine the affinities and
kinetic properties of RNA binding by RIG-I CTD, we expressed2010 Elsevier Ltd All rights reserved 1033
Figure 2. RIG-I CTD Binds 50 Triphosphate (ppp) dsRNA with High Affinity
(A) Equilibrium binding study of RIG-CTD with the 14-bp GC-rich 50 ppp dsRNA by surface plasmon resonance (SPR). The dissociation constant (Kd) was derived
by fitting of the equilibrium binding data to a one site binding model (lower panels).
(B) Equilibrium binding study of RIG-I CTD with the 14-bp blunt-ended dsRNA.
(C) Equilibrium binding study of RIG-I CTD with a 13-nt 50 ppp ssRNA.
(D) Kinetic binding studies of RIG-CTD with the 14-bp GC-rich 50 ppp dsRNA. The association and dissociation rate constants (kon and koff) were derived from
global fitting of the binding data to a 1:1 binding model (red curves). Half-life (t1/2) for each of the RNA: RIG-I CTD complex was calculated from the koff. The calcu-
lated dissociation constant (KD, calc) was derived by division of the dissociation rate constant (koff) by the association rate constant (kon).
(E) Kinetic binding studies of RIG-I CTD with the 14-bp blunt-ended dsRNA.
(F) Kinetic binding studies of RIG-I CTD with the 13-nt 50 ppp ssRNA.
Structure
Structure of RIG-I CTD Bound to dsRNAand purified GST-RIG-I CTD and conducted RNA binding
studies by surface plasmon resonance (SPR). Equilibrium
binding studies showed that the affinity of RIG-I CTD for the
14-bp 50 ppp dsRNA is 0.32 ± 0.05 nM (Figure 2A). The affinity
of RIG-I CTD for the 14-bp dsRNA without 50 ppp is 4.6 ± 0.6
nM (Figure 2B), about 15 times lower than the affinity for the 50
ppp dsRNA. The 13-nt 50 ppp ssRNA binds RIG-I CTD with an
affinity of 7.6 ± 0.9 nM (Figure 2C). The calculated dissociation
constants (KD,calc = koff / kon) derived from the kinetic binding
studies are similar to those derived from the equilibrium binding
studies (Figure 2). Although RIG-I CTD interacts with RNA1034 Structure 18, 1032–1043, August 11, 2010 ª2010 Elsevier Ltd Aprimarily through electrostatic interactions, binding of the
14-bp 50 ppp dsRNA by RIG-I CTD shows slow association
rate and slow dissociation rate (Figure 2D), suggesting that
conformational change of the protein is likely needed for RNA
binding. It is possible that other types of interactions, such
as hydrogen bonding and hydrophobic interactions, may also
contribute to RNA binding. In contrast, the binding of blunt-
ended dsRNA lacking a 50 ppp shows faster association and
dissociation rates (Figure 2E). Binding of the 13-nt 50 ppp ssRNA
shows kinetic properties similar to that of the 50 ppp dsRNA
(Figure 2F). These results indicate that the 50 ppp plays anll rights reserved
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Figure 3. Structures of RIG-I CTD Bound to 50 Triphosphate (ppp)
Double-Stranded RNA
(A) Crystal structure of RIG-I CTD bound to the 14-bp GC-rich 50 ppp dsRNA.
The nucleotides at the 50 ends of the dsRNA containing the triphosphate are
shown as space filling models. The zinc ions bound to RIG-I CTD are shown
as gray spheres.
(B) Structure of the RIG-I CTD bound to the 12-bp AU-rich 50 ppp dsRNA. The
orientations of RIG-I CTD (Chain A) relative to the dsRNA are the same in the
two structures.
Structure
Structure of RIG-I CTD Bound to dsRNAimportant role in determining the kinetic properties of RNA
binding by RIG-I CTD. The higher affinity of the 50 ppp dsRNA
and the longer half-life (t1/2 = 327 ± 2 s) of its complex with
RIG-I suggest that dsRNA with 50 ppp should be more potent
stimulator of RIG-I.RIG-CTD Recognizes the Termini of 50 ppp dsRNA
To elucidate the structural basis of 50 ppp dsRNA recognition by
RIG-I, we determined the crystal structures of RIG-I CTD (resi-
dues 803 to 923) bound to a 14-bp GC-rich dsRNA (with self-
complementary sequence of 50 pppGGCGCGCGCGCGCC 30)
and a 12-bp AU-rich dsRNA (with self-complementary sequence
of 50 pppAUAUAUAUAUAU 30). The structures were determined
by molecular replacement and refined at 2.6 and 2.15 A˚ resolu-
tion, respectively. Crystals of the 12-bp AU-rich dsRNA complex
are merohedrally twinned. The structure was refined against the
twinned data using CNS (Brunger et al., 1998). Statistics of data
collection and structural refinement are listed in Table 1.
Consistent with the stoichiometry determined by AUC, the
crystallographic asymmetric units for the two complex crystals
contain a 2:1 complex between RIG-I CTD and the dsRNA
(Figures 3A and 3B). The complexes exhibit pseudo two-fold
symmetry along the two-fold axis of the palindromic dsRNA.Structure 18, 1032–The orientations of the dsRNA relative to the RIG-I CTD in the
two complexes are similar (Figure 3). The 50 triphosphate of the
dsRNA are well defined at the four binding sites in the two com-
plexes and interact with the protein in similar ways (Figure S2).
Structures of four RIG-I CTDs in the two complexes are similar;
the root mean square deviations (rmsd) between the Ca atoms
of RIG-I CTD within each complex or between the two com-
plexes are only 0.3 to 0.5 A˚. Discussions of the complex structure
below are based on the structure of RIG-I CTD (Chain A) in the
14-bp GC-rich dsRNA complex because of the better-defined
electron density map at this interface (Figure S2) and more
complete diffraction data used in the structural refinement
(Table 1).
As predicted from our previous structural studies of the LGP2
CTD:dsRNA complex (Li et al., 2009b), RIG-I CTD recognizes
the termini of the 50 ppp dsRNA (Figure 3). The dsRNA in the
complex adopts a typical A-form double helical structure. The
RNA-binding surface of RIG-I CTD is located at a large
saddle-shaped surface defined by the hairpin containing
strands b3 and b4, the loop connecting strands b5 and b6,
the b sheet containing strands b5 to b8, the loop connecting
strands b8 and b9, and the loop connecting strand b10 to the
C terminus (Figure 4A). RIG-I CTD interacts with the dsRNA
primarily through extensive electrostatic interactions with the
50 ppp and the phosphodiester backbone (Figures 4A and 4B).
The exposed base pairs at the termini of the dsRNA interact
with RIG-I CTD through hydrophobic interactions (Figure 4B).
The RNA-binding surface of RIG-I CTD exhibits a high degree
of shape and charge complementarity to the blunt-ends of 50
ppp dsRNA (Figure 4C). The total buried surface area at the
RIG-CTD:dsRNA interface is 1200 A˚2, with primary contribu-
tions from the first four nucleotides at the 50 end of the dsRNA
(buried surface area of 900 A˚2). The last three nucleotides at
the 30 end of the complementary strand make only minor contri-
butions to dsRNA binding (buried surface area of 300 A˚2). The
average shape correlation statistic (Sc) is 0.62 for the four1043, August 11, 2010 ª2010 Elsevier Ltd All rights reserved 1035
Figure 4. Structural Basis of 50 Triphos-
phate (ppp) dsRNA Recognition by RIG-I
CTD
(A) Stereo close-up of the interface between RIG-I
CTD (Chain A) and the terminus of the 14-bp 50
ppp dsRNA. RIG-I CTD is shown as cyan ribbons
and the dsRNA is shown as stick models. Key resi-
dues of RIG-I CTD involved in RNA binding are
shown as stick models.
(B) Stereo close-up of the interactions between
RIG-I CTD and the 50 ppp of the 14-bp GC-rich
dsRNA.
(C) Surface representation of RIG-I CTD bound to
50 ppp dsRNA showing the shape and charge
complementarity between RIG-I CTD and the
terminus of the 50 ppp dsRNA. Positively charged
surfaces are colored blue, and negatively charged
surfaces are red. The orientation of RIG-I CTD rela-
tive to the dsRNA on the left panel is similar to the
orientation of the protein in panel A.
Structure
Structure of RIG-I CTD Bound to dsRNAdsRNA protein interfaces; the Sc value is a measure of the
degree to which two contacting surfaces are geometrically
matched, with an Sc value of 1.0 indicating a perfect fit (Law-
rence and Colman, 1993).
The overall structure of RIG-I CTD in the complex is similar to
the structure of RIG-I CTD in isolation (rmsd of 0.7 A˚). The
largest structural difference between free and RNA bound RIG-I
CTD occurs at the loop between strands b5 and b6 (loop 5–6)
from His847 to Ser855 (Figure S3). The average deviation for
the Ca atoms of these eight residues is 1.67 A˚ in the two struc-
tures. As reflected in the nine structures of RIG-I CTD in the crys-
tallography asymmetric unit, this loop is highly flexible in the
structures of RIG-I CTD in isolation (Cui et al., 2008). The structure
of RIG-I CTD in solution also revealed that this loop is flexible
(Takahasi et al., 2008). However, the four structures of the RIG-I1036 Structure 18, 1032–1043, August 11, 2010 ª2010 Elsevier Ltd All rights reservedCTD in the two complexes are highly
similar, suggesting that dsRNA binding
stabilizes the specific conformation of
loop 5–6.
Structural Basis of 50 ppp dsRNA
Recognition by RIG-I CTD
As predicted from previous mutagenesis
studies (Cui et al., 2008; Takahasi et al.,
2008), the 50 triphosphate–binding site
of RIG-I is located at a large patch of posi-
tively charged surface around residues
Lys858 and Lys861. Four positively
charged residues interact with the 50
ppp through electrostatic interactions
(Figures 4A and 4B; Table S2). Lys888
interacts with the a-phosphate group
through electrostatic interaction (Figures
4A and 4B). The distance between the
side chain amine group of Lys888 and
the a-phosphate is only 2.4 A˚. The side
chain amine group of Lys861 is 2.7 A˚
away from the a- and b-phosphates, in-teracting simultaneously with these two phosphate groups
(Figures 4A and 4B; Table S2). Proper positioning of the side
chains of Lys888 and Lys861 to interact with the a- and b-phos-
phate is facilitated by Asp872, which interacts with the side
chains of these two residues through electrostatic interactions
(Figure 4B). The b-phosphate also interacts with the side chains
of Lys858 and His847 simultaneously (Figure 4B). In addition,
Lys858 also interacts with the g-phosphate that is about 5 A˚
away from the side chain amine groups of Lys849 and Lys851
(Figure 4B). These two positively charged residues may interact
with the ppp through weak electrostatic interaction or solvent-
mediated hydrogen bonds.
Although the electrostatic interactions between RIG-I CTD and
the 50 ppp play dominant roles in dsRNA binding, RIG-I CTD
interacts extensively with other parts of the dsRNA (Table S2).
Figure 5. Distinct Binding by RIG-I and LGP2 CTDs to dsRNA with
and Without 50 Triphosphate (ppp)
Stereo representation of the structure of RIG-I CTD bound to the 14-bp GC-
rich 50 ppp dsRNA superimposed on the structure of LGP2 CTD bound to an
8-bp dsRNA without 50 ppp. The 14-bp 50 ppp dsRNA bound to RIG-I CTD
is shown as blue ribbons. The 8-bp dsRNA bound to LGP2 CTD is colored
magenta. A 14-bp dsRNA (orange) is superimposed on the 8-bp dsRNA in
the LGP2 CTD:dsRNA complex structure to show the different orientations
of the dsRNA relative the proteins in the two complexes.
Structure
Structure of RIG-I CTD Bound to dsRNAThe exposed base pair at each terminus of the dsRNA interacts
with Phe853 through hydrophobic interaction, and the guanine
base at the 50 end of the RNA stacks against the phenyl side
chain of Phe853 (Figure 4B). The side chain of His830 forms
a hydrogen bond with the 20 hydroxyl group of nucleotide G1
(Figure 4B). This hydroxyl group also forms two solvent-medi-
ated hydrogen bonds with the backbone amine of Tyr831 and
the carbonyl group of Ile887 (Table S2). The phosphate group
of G1 forms two solvent-mediated hydrogen bonds with
Ser906 and Trp908 (Table S2). The third nucleotide C2 from
the 50 end forms a solvent-mediated hydrogen bond with the
backbone amine of Trp908 (Table S2). In addition, the phosphate
group of G3 interacts with the side chain of Lys907 through elec-
trostatic interactions (Figure 4A). However, the RNA does not
interact with the nearby Lys909 directly. The side chains of
Lys849 and Lys851 are in close proximity to the phosphate of
C10 and G11 near the 30 end of the RNA (Figure 4A). However,
the electron density map for the side chains of these two resi-
dues is poorly defined, reflecting their flexibility and limited
contribution to dsRNA binding. The side chain hydroxyl of
Ser854 forms a hydrogen bond with the 20 hydroxyl at the 30
terminal nucleotide (C13) of the complementary strand (Table
S2). Apart from the hydrophobic interactions between the
terminal bases and Phe853, no other specific interaction
between RIG-I CTD and the bases was observed in the two
complex structures, demonstrating that RIG-I CTD binds RNA
in a sequence-independent manner.RIG-I and LGP2 Bind dsRNA with and Without 50 ppp
in Different Ways
The crystal structures of RIG-I and LGP2 CTD bound to dsRNA
with and without 50 ppp, respectively, allowed us to elucidate
how the RLRs recognize these two different forms of dsRNA.
To facilitate this comparison, we superimposed a 14-bp dsRNA
onto the structure of LGP2 CTD bound to an 8-bp dsRNA (Li
et al., 2009b). Superposition of LGP2 CTD onto the structure of
RIG-I CTD bound to the 14-bp GC-rich dsRNA revealed that
the orientations of the dsRNA in the two complexes are dramat-
ically different (Figure 5). Although both proteins recognize the
terminus of the dsRNA and similar binding surfaces are involved
in RNA binding, the 14-bp 50 ppp dsRNA was rotated by 30
away from RIG-I CTD compared to the 14-bp dsRNA in the
LGP2 CTD:dsRNA complex model (Figure 5). As a result, RIG-I
CTD has less-extensive interactions with the 50 ppp dsRNA
compared to the interactions between the blunt-ended dsRNA
and LGP2 CTD (Li et al., 2009b). The total buried surface area
at the LGP2 CTD:dsRNA interface (1540 A˚2) is about 30%
larger than that of the RIG-I CTD:dsRNA interface. The interface
between LGP2 CTD and the blunt-ended dsRNA also exhibits
a higher degree of shape complementarity (Sc = 0.75). Although
the interaction between LGP2 CTD and dsRNA is more exten-
sive, the affinity of LGP2 CTD for a 10-bp blunt-ended dsRNA
without ppp is about 100 nM (Li et al., 2009b). In addition, tri-
phosphorylated dsRNA exhibits a slightly lower affinity for
LGP2 CTD (Li et al., 2009b). Furthermore, mutations that disrup-
ted RNA binding by LGP2 do not affect its ability to regulate RIG-I
signaling (Li et al., 2009b). These results suggest that LGP2 does
not regulate RIG-I signaling through direct competition withStructure 18, 1032–RIG-I for ligand binding, indicating that the RIG-I-RNA interaction
is different from that of LGP2-RNA interaction.
Because the 50 ppp has to be positioned precisely into the
triphosphate-binding site, this structural requirement determines
the specific orientation of the 50 ppp dsRNA relative to RIG-I
CTD. Because the ppp makes primary contributions to 50 ppp
dsRNA binding by RIG-I CTD, the binding affinity of blunt-
ended dsRNA without ppp should be much lower than that of
the 50 ppp dsRNA; the buried surface area between a dsRNA
without 50 ppp and RIG-I CTD will be reduced to 1050 A˚2 if
the RNA still binds RIG-I in the same orientation. Interestingly,
SPR binding studies show that RIG-I CTD binds the 14-bp
dsRNA without the 50 ppp at nanomolar affinity. It is possible
that RIG-I CTD binds blunt-ended dsRNA lacking a ppp in a
similar way as LGP2 CTD to increase the binding interactions.
Because dsRNA with or without ppp both activate RIG-I
in vivo, we propose that the two forms of RNA may trigger the
activation of RIG-I through different mechanisms.Similar Binding Surfaces of RIG-I CTD Mediate
Its Interactions with Different Forms of RNA
On the basis of the structures of RIG-I CTD bound to 50 ppp
dsRNA, we expressed and purified 12 mutant proteins of RIG-I
CTD and studied their binding properties with a 50 ppp dsRNA,
a blunt-ended dsRNA, and a 50 ppp ssRNA by electrophoretic
mobility shift assay (EMSA). Ten of these 12 mutants were also
analyzed for RNA binding by gel filtration chromatography.
First, mutation of each of the three positively charged resi-
dues—Lys858, Lys861, and Lys888—that are involved in direct
contact with the 50 ppp to a negatively charged glutamate almost
abolished 50 ppp dsRNA and ssRNA binding in the gel shift
assays (Figure 6). Consistent with these results, no binding for
50 ppp ssRNA and dsRNA were observed for these mutants by
gel filtration chromatography (Figure S4). Similarly, mutation of
Lys888 to glutamate also abolished blunt-end dsRNA binding
(Figure 6). However, substitutions of either Lys858 or Lys8611043, August 11, 2010 ª2010 Elsevier Ltd All rights reserved 1037
Figure 6. Similar Binding Surfaces of RIG-I
CTD Mediate the Interactions with Different
Forms of RNA
(A) Binding studies of wild-type and mutants of
RIG-I CTD for the 14-bp 50 triphosphate (ppp)
dsRNA by electrophoretic mobility shift assay
(EMSA).
(B) Binding studies of RIG-I CTD mutants with
a 14-bp blunt-ended dsRNA lacking 50 ppp.
(C) Binding studies of RIG-I CTD mutants with
a 13-nt 50 ppp ssRNA.
Structure
Structure of RIG-I CTD Bound to dsRNAby glutamate dramatically reduced but did not abolish blunt-
ended dsRNA binding (Figure 6; Figure S4). Substitution of
His847 that interacts directly with the b-phosphate with a gluta-
mate significantly reduced the binding of 50 ppp dsRNA and
ssRNA, but only slightly reduced the binding of blunt-ended
dsRNA (Figure 6; Figure S4). Consistent with these results, muta-
tions of both His847 and Lys861 to glutamate disrupted binding
of 50 ppp dsRNA or ssRNA and nearly abolished blunt-ended
dsRNA binding (Figure 6). Second, we analyzed the effects of
mutations of four other positively charged residues—Lys849,
Lys851, Lys907, and Lys909—on RNA binding. Mutation of
Lys907 that interacts with the phosphodiester backbone of the
dsRNA to glutamate dramatically reduced binding for all three
forms of RNA (Figure 6), demonstrating the critical role of this
residue in recognizing the RNA backbone. Gel filtration chroma-
tography confirmed that mutant K907E failed to bind all three
forms of RNA (Figure S4). In contrast, substitution of the nearby
Lys909 with a glutamate reduced the binding of 50 ppp dsRNA
but almost abolished the binding of blunt-ended dsRNA and 50
ppp ssRNA (Figure 6; Figure S4). Mutations of either Lys849 or
Lys851 to glutamate reduced binding for all three forms of
RNA, but did not abolish RNA binding (Figure 6; Figure S4). Third,
we analyzed the mutations of His830, Phe853, and Asp872 that
interact with the dsRNA through hydrogen bonding, hydro-
phobic interactions, or facilitate the binding of the ppp group.
Replacement of Asp872 with an alanine did not affect RNA
binding (Figure 6; Figure S4). Mutation of His830 to alanine did
not affect 50 ppp dsRNA or ssRNA binding, but reduced blunt-
ended dsRNA binding (Figure S4). Although gel shift assays
showed that substitution of Phe853 by serine did not affect RNA
binding significantly (Figure 6), gel filtration chromatography1038 Structure 18, 1032–1043, August 11, 2010 ª2010 Elsevier Ltd All rights reservedshowed that this mutation dramatically
reduced triphosphorylated RNA binding
and nearly abolished blunt-ended dsRNA
binding (Figure S4).
These mutagenesis and binding
studies demonstrated that the binding
surface observed in the complex struc-
tures mediates RNA binding by RIG-I
CTD in solution. It is also important to note
that, although similar binding surfaces
are involved in contacting blunt-ended
dsRNA as well as dsRNA and ssRNA
with 50 triphosphate, the fact that muta-
tions in the CTD can differentially affectbinding of the three forms of RNA illustrates distinct recognition
of these RNA ligands by RIG-I.
Mutations of Key Residues at the RNA-Binding Surface
Affect RIG-I Signaling
The 12 mutations tested for RNA binding were built into
constructs of full-length RIG-I to assess how these mutations
affect RIG-I signaling in transiently transfected HEK293T cells.
The cells were first transfected to express the RIG-I mutants
along with the IFN-b luciferase reporter plasmids. Expression
of wild-type RIG-I and various mutants in the transfected cells
was confirmed by western blot (Figure 7A). After 24 hr, different
RNA ligands were transfected into the cells to analyze their abil-
ities to activate RIG-I–dependent signaling. A 24-bp 50 ppp
dsRNA, a 27-nt 50 ppp ssRNA, and a 27-bp blunt-ended dsRNA
were tested in these assays. The relative activities of triphos-
phorylated RNAs are similar, whereas the blunt-ended dsRNA
is slightly less active (Figure S5).
First, we analyzed signaling of mutants modified at residues
that play critical roles in the recognition of the 50 ppp group.
Because the Ca atom of Lys888 is only 3.8 A˚ away from the
G1 phosphate and its side chain amine group interacts with
the a-phosphate of the 50 ppp, substitution of Lys888 by gluta-
mate disrupted RNA binding by RIG-I CTD and abolished RIG-I
signaling by 50 ppp dsRNA or ssRNA and blunt-ended dsRNA
(Figure 7). Although mutation of Lys861 to glutamate did not
affect signaling by blunt-ended dsRNA, it did disrupt signaling
by 50 ppp dsRNA and ssRNA (Figure 7). Similarly, mutation of
Lys858 to glutamate reduced signaling by blunt-ended dsRNA
by about 50% and abolished signaling by 50 ppp dsRNA and
ssRNA (Figure 7). Substitution of His847 by a glutamate did not
Figure 7. Mutations of Key Residues at the
RNA-Binding Surface Affect RIG-I Signaling
(A) Western blot showing the expression of wild-
type and mutants of full-length RIG-I in transfected
cells.
(B) IFN-b luciferase assay showing the signaling of
wild-type and mutants of RIG-I in HEK293T cells
stimulated with a 24-bp 50 triphosphate (ppp)
dsRNA. Error bars correspond to the standard
deviations of signals from three independent
transfections.
(C) IFN-b luciferase assay showing the signaling of
wild-type and mutants of RIG-I in cells stimulated
with a 27-nt 50 ppp ssRNA.
(D) IFN-b luciferase assay showing the signaling of
wild-type and mutants of RIG-I in cells stimulated
with a 27-bp blunt-ended dsRNA without the 50
ppp.
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Structure of RIG-I CTD Bound to dsRNAaffect blunt-ended dsRNA signaling, but it reduced signals from
both 50 ppp dsRNA and ssRNA dramatically (Figure 7). Second,
substitutions of Lys907 and Lys909 by glutamates disrupted
signaling for all three forms of RNA (Figure 7). In contrast, muta-
tions of either Lys851 or 849 to glutamate did not affect signaling
of blunt-end dsRNA or 50 ppp dsRNA or ssRNA (Figure 7). Third,
we tested signaling of mutants of RIG-I at residues His830,
Phe853, and Asp872 that have slightly reduced RNA binding.
We found that mutations C829S/H830A or D872A had no effect
on the signaling of RIG-I for any of the three forms of RNA tested
(Figure 7). Consistent with these results, a Cys829 to serine
substitution in RIG-I CTD did not affect RNA binding in vitro
(Figure S4). The slightly higher activity of these two mutants
compared to the wild-type protein is likely the result of their
higher expression level or better stability in the cells. However,
replacement of the hydrophobic Phe853 by a hydrophilic serine
reduced signaling of 50 ppp dsRNA or ssRNA by about 70% and
reduced signaling by blunt-ended dsRNA to background level
(Figure 7), demonstrating that Phe853 has a role in RNA sensing
by RIG-I. These results are consistent with RNA-binding proper-
ties of RIG-I CTD mutants, demonstrating that RNA binding by
RIG-I CTD is essential for RIG-I signaling and RNA with or
without ppp can activate RIG-I in vivo.
DISCUSSION
RNA binding studies showed that RIG-I CTD binds 50 ppp dsRNA
or ssRNA and blunt-ended dsRNA, with the highest affinity for 50
ppp dsRNA. IFN-b luciferase assays demonstrated that all threeStructure 18, 1032–1043, August 11, 2010 ªforms of RNA could stimulate RIG-I
signaling. The structures of RIG-I CTD
bound to 50 ppp dsRNA showed that
RIG-I recognizes the termini of RNA and
interacts with the 50 ppp as well as the
backbone phosphodiesters of the RNA.
Mutagenesis and RNA binding studies
demonstrated that similar binding
surfaces of RIG-I CTD are involved in
the binding of various forms of RNA by
RIG-I. These results provide a structuralframework to understand the RNA binding properties and func-
tions of RIG-I in antiviral immune responses.
The complex structures showed that RIG-I CTD interacts
primarily with the 50 four nucleotides of the dsRNA. The comple-
mentary RNA strand makes only limited contributions to RNA
binding (Figure 4; Table S2). These observations explain how
RIG-I CTD can bind both dsRNA and ssRNA with ppp.
The amino acid residues of RIG-I involved in RNA binding can
be divided into three groups. The first group of residues
includes Lys888, Lys858, Lys861, and His847 that recognize
the 50 ppp of dsRNA. The second group of residues includes
Lys907 and Lys909 that interact with the phosphate backbone
of the dsRNA. The third group of residues interacts with the
exposed bases at the termini of the RNA or interacts with the
backbone of the RNA by hydrogen bonds. The first two groups
of residues contribute to RNA binding through multiple electro-
static interactions, whereas the third group of residues makes
additional contributions to RNA binding through hydrogen
bonds and hydrophobic interactions. All these residues con-
tribute to the binding of RNA with 50 ppp, whereas the last two
groups of residues contribute primarily to the binding of dsRNA
without 50 ppp. Importantly, these structural features explain
how RIG-I can recognize such a wide range of RNA ligands,
including 50 ppp dsRNA and ssRNA, as well as dsRNA without
50 ppp.
The reason why ssRNA without ppp failed to bind RIG-I CTD is
most likely due to the loss of the critical electrostatic interactions
mediated by the ppp group. However, dsRNA without ppp still
binds RIG-I CTD at high affinity, and this is due to the additional2010 Elsevier Ltd All rights reserved 1039
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(P.L., unpublished data).
Because the a- and b-phosphates make major contributions
to the recognition of the 50 ppp by RIG-I, the complex structures
also explain why dsRNA with one or two 50-terminal phosphates
can serve as ligands for RIG-I (Figure 4B). Previous studies
showed that blunt-ended 50 ppp dsRNA are potent activators
of RIG-I, whereas 50 ppp dsRNA with 50 overhangs still stimulated
RIG-I but 50 ppp dsRNA with 30 overhangs failed to stimulate
RIG-I (Schlee et al., 2009b). However, our RNA binding studies
showed that all three forms of dsRNA bind RIG-I CTD efficiently
(Figure S1). Although the complex structures indicated that
dsRNA with 30 overhangs can still bind RIG-I effectively, the
reason why 50 ppp dsRNA with 30 overhangs failed to stimulate
RIG-I is most likely that these RNA molecules are unwound by
RIG-I (Takahasi et al., 2008). The structures suggest that ppp
dsRNA with 50 overhangs should exhibit significantly reduced
affinity for RIG-I just like 50 ppp ssRNA, explaining why this
kind of RNA is less effective in stimulating the activation of
RIG-I (Schlee et al., 2009b).
Our binding studies showed that RIG-I CTD binds the GC- and
AU-rich RNA with similar affinities. In addition, the two complex
structures showed that RIG-I binds the two kinds of RNA in
almost the same way with no specific interactions between the
protein and the bases (Figure 3). These results indicate that
RIG-I CTD is not responsible for the recognition of specific
RNA sequences, such as the polyuridylates or polyadenylates
sequences observed in the 30 nontranslated regions of hepatitis
C virus genome (Saito et al., 2008). The studies by Chiu et al.
(2009) showed that poly (dA-dT) DNA transfected in cells can
activate RIG-I as a result of transcription of these DNA
sequences by RNA polymerase III, whereas GC-rich DNA failed
to activate RIG-I when transfected into cells. This is not likely due
to the different sequences of DNA but most likely due to the inef-
ficient transcription of GC-rich DNA by RNA polymerase III that
need the poly (dA-dT) sequence to initiate transcription. In
summary, the ability of RIG-I to recognize a broad range of
RNA structures without sequence specificity allows the receptor
to sense the infection of a wide spectrum of viruses.
The crystal structures of RIG-I and LGP2 CTD in isolation and
in complex with dsRNA are now available (Cui et al., 2008; Li
et al., 2009b; Pippig et al., 2009). The 1.45 A˚ resolution structure
of MDA5 CTD has also been determined (Li et al., 2009a). These
structures revealed that the CTD of the RLRs are highly
conserved and that similar binding surfaces are involved in
RNA binding by all the three proteins (Figure S3). The structures
of RIG-I CTD and LGP2 CTD bound to dsRNA with and without 50
ppp demonstrated that the RLRs recognize the termini rather
than the ribose-phosphate backbone of various forms of RNA
(Figure 5). However, the three proteins exhibit different ligand-
binding properties and play different roles in antiviral immune
responses. Comparisons of the structures of RIG-I CTD in
complex with triphosphorylated dsRNA and LGP2 CTD in
complex with blunt-ended dsRNA revealed that the orientations
of the RNA are significantly different (Figure 5). This finding
suggests that the triphosphorylated and blunt-ended dsRNA
interact with RIG-I differently and probably induce different
conformations of full-length RIG-I upon binding. This idea is
further supported by the differential binding of triphosphorylated1040 Structure 18, 1032–1043, August 11, 2010 ª2010 Elsevier Ltd AdsRNA and blunt-ended dsRNA by RIG-I CTD mutants (Figure 6)
and the abilities of RIG-I mutants to activate luciferase reporters
in cells stimulated with different forms of RNA (Figure 7).
Comparisons of the ligand-binding surfaces of the RLR CTDs
showed that the surface electrostatic potential of the three
proteins are dramatically different (Figure S3). For the four posi-
tively charged residues in RIG-I CTD that are responsible for the
ppp recognition, only Lys888 is conserved in the sequences of
LGP2 and MDA5 CTDs. Consistent with this observation, both
MDA5 and LGP2 CTDs bind 50 ppp dsRNA with lower affinities
than blunt-ended dsRNA (Li et al., 2009a; Li et al., 2009b). It is
evident that RIG-I is the only RLR that is responsible for the
sensing of 50 ppp RNA. Because RIG-I can also be activated
by dsRNA without 50 ppp, which is also recognized by MDA5,
this could explain why RIG-I and MDA5 sense distinct but over-
lapping sets of viruses.
A number of factors may affect the results of RIG-I activation
assays in vivo. The structure and purity of RNA ligands, their
binding affinities for RIG-I, their effective concentrations in cells,
and their stabilities will all affect the signal readout. Previous
studies used various cell lines and different assays to demon-
strate that various RNA ligands can activate signal transduction
through RIG-I (Schlee et al., 2009a). Our studies demonstrated
that dsRNA with or without 50 ppp and ssRNA with 50 ppp are
the three major families of RNA that activate RIG-I. Furthermore,
blunt-ended dsRNA with or without 50 ppp are more effective
agonists for RIG-I signaling than dsRNA with overhangs (Li
et al., 2009b; Schlee et al., 2009a, 2009b; Takahasi et al.,
2008). Consistent with these findings, all these three families of
RNA bind RIG-I CTD and blunt-ended dsRNA with 50 ppp binds
RIG-I CTD at a significantly higher affinity (Figures 1 and 2).
Results from the IFN-b luciferase reporter assays confirmed
that all these three families of RNA stimulate RIG-I signaling in
cells (Figure 7). In contrast, two recent studies showed that only
dsRNA with 50 ppp activates RIG-I in human monocytes (Schlee
et al., 2009b; Schmidt et al., 2009). It is likely that the different
assay techniques or the difference in the effective concentration
of ligands in the transfected cells account for these discrep-
ancies. Because the affinities of blunt-ended dsRNA and 50 ppp
ssRNA are about 15-fold lower than that of blunt-ended 50 ppp
dsRNA, significantly higher concentration of blunt-ended dsRNA
is needed for the activation of RIG-I. A number of other reports,
including one of our previous studies, also demonstrated that
dsRNA without 50 ppp can activate RIG-I (Li et al., 2009b; Taka-
hasi et al., 2008). In addition, it has been shown that RNase diges-
tion of dsRNA mimetic poly I:C converted it from a ligand of MDA5
into a ligand for RIG-I (Kato et al., 2008). Moreover, the digestion
of self-RNA by antiviral endonuclease RNase L generates small
RNA products that initiate interferon production (Malathi et al.,
2007). It is likely that higher concentration of ligands generated
by RNase digestion triggers the activation of RIG-I.
Structural studies of RIG-I and LGP2 CTD bound to dsRNA
provided important insight into the structural basis of viral RNA
recognition by the RLRs. However, the mechanism of how
RNA binding triggers the activation of RIG-I or MDA5 remains
to be established. Although electron microscopy studies of
RIG-I and LGP2 in isolation and in complex with dsRNA provided
some information about how these proteins might bind RNA
(Murali et al., 2008; Ranjith-Kumar et al., 2009), the detailedll rights reserved
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determination of the high resolution structures of the full-length
proteins bound to RNA.
EXPERIMENTAL PROCEDURES
Purification of RIG-I CTD and Its Complexes with 50 ppp dsRNA
The cDNA encoding the human RIG-I CTD (residues 802 to 925) was cloned into
bacterial expression vectorpET22b(+) (Novagen). ResidueCys829 was mutated
to serine to prevent dimerization of the protein. The cloned DNA sequence was
confirmed by plasmid sequencing. RIG-CTD was expressed in Escherichia coli
strain BL21(DE3) by induction at OD600 = 0.6–0.8 with 0.4 mM isopropyl-b-D-
thiogalactoside (IPTG) overnight at 15C. The protein was purified by nickel
affinity chromatography on a His-Select nickel affinity resin (Sigma-Aldrich)
column. The protein was further purified by gel filtration chromatography on
a Superdex75 (1.63 60) column (GE Healthcare) eluted with a buffer containing
20 mM Tris and 150 mM NaCl (pH 7.50; buffer A). The two dsRNA constructs
used to form complexes with RIG-I CTD were generated by in vitro transcription
using T7 RNA polymerase and purified by gel filtration chromatography on
a Superdex75 (1.6 3 60) column. RIG-I CTD was mixed with the 14-bp or the
12-bp dsRNA at a molar ratio of about 3:1, and the 2:1 (RIG-I CTD:dsRNA)
complexes were purified by gel filtration chromatography on a Superdex75
(1.63 60) column eluted with buffer A. After purification, 5 mM DTT was added
to the complexes, and the samples were concentrated for crystallization.
RNA Binding Studies by Gel Filtration Chromatography
Different forms of RNA were generated by either chemical synthesis or in vitro
transcription using T7 RNA polymerase. All in vitro–transcribed RNA were puri-
fied by gel filtration chromatography and analyzed by denaturing polyacryl-
amide gel electrophoresis. Each of the purified ppp RNA showed a single
band with the expected length on the denaturing gels. Sequences of the
RNAs used in this study are shown in Table S1. Double-stranded RNA was
generated by heating the ssRNA at 95C for 5 min and cooling gradually to
room temperature. For the binding studies, each of the RNA samples
(at 100 mM) was mixed with equal volume of RIG-I CTD (at 200 mM), and
100 ml of samples were injected over a Superdex200 (10/300 GL) column
(GE Healthcare) eluted with buffer A. The column was calibrated with a set
of protein standards of different sizes (Bio-Rad) to allow the estimation of
the sizes of the protein and RNA complexes.
Analytical Ultracentrifugation
To determine the stoichiometry of RIG-I CTD binding to the 14 bp 50 ppp
dsRNA, purified RIG-I CTD:14 bp dsRNA complex was analyzed by AUC.
For sedimentation velocity experiments, 400 ml samples in 20 mM Tris-HCl
buffer (pH 7.5), 150 mM NaCl, and 10 mM b-mercaptoethanol were centrifuged
overnight at 48,000 rpm at 10C in a Beckman XL-I using absorbance optics at
304 nm. The data were analyzed by the program Sedfit using the c(s) and c(M)
models to determine differential sedimentation coefficient and apparent mass
distributions, respectively. The complex sedimented as a single peak, with
a sedimentation coefficient of 2.72 S and an estimated molecular mass of
38 kDa, similar to that expected for a 2:1 complex (38.5 kDa). To confirm the
stoichiometry, the complex was analyzed in a sedimentation equilibrium
experiment. Briefly, 100 ml of samples of the complex at concentrations of
15, 50, and 150 mM were spun at 19,000, 22,500, and 33,000 rpm at 10C until
equilibrium was reached, and were scanned at 295 and 306 nm. The data of
the sedimentation equilibrium experiments were analyzed as described else-
where (Li et al., 2009b). Global analysis of nine data sets revealed that the
data could be described by a single species with a reduced buoyant molecular
weight of 1.883 (at 19,000 rpm). To convert to experimental molecular weight,
the partial specific volume must be known; for a protein and RNA complex, this
value corresponds to the weight average of each component in the sediment-
ing species. The partial specific volume for RIG-I CTD alone was calculated
to be 0.7258 mL/g at 10C using Sednterp. The partial specific volume for
the 14-bp dsRNA was calculated to be 0.5688 mL/g using the NucProt Calcu-
lator server (http://www.molmovdb.org/cgi-bin/psv.cgi) and corrected to 10C
in Sednterp. Both 2:1 and 2:2 complexes were considered, with weight-
average partial specific volumes of 0.6956 or 0.6716 mL/g, respectively. TheStructure 18, 1032–molecular weight values calculated from the reduced buoyant molecular
weight and appropriate partial specific volumes were only self-consistent in
the case of a 2:1 complex, yielding an experimental molecular weight of
37,339 Da (95% confidence interval, 33,882–40,796 Da).
RNA Binding Studies by Surface Plasmon Resonance
Binding interactions between RIG-CTD and three different forms of RNA were
analyzed by SPR at 25C in HBS-EP+ (10 mM HEPES [pH 7.4], 150 mM NaCl,
3 mM EDTA, and 0.05% v/v P-20 surfactant) buffer on a Biacore T100 system
(GE Healthcare). The goat anti-GST mAb (Biacore AB) at 30 mg/ml in 10 mM
sodium acetate (pH 5.0) was immobilized on a CM5 sensor chip (Biacore) by
standard amine coupling chemistry. Immobilization of 13,000 response units
(RU) of the antibody resulted in optimal responses in subsequent analyses.
GST-RIG-CTD (at 5 mg/ml) was captured over the immobilized anti-GST
mAb surface at a flow rate of 10 ml/min for 120 s to reach 1,200 RU response.
For equilibrium binding studies, dilution series of different forms of RNA were
injected in randomized duplicate runs at flow rates of 30, 50, and 50 ml/min for
10, 7, and 5 min for the 14-bp 50 ppp dsRNA, the 14-bp blunt-ended dsRNA,
and the 13-nt 50 ppp ssRNA, respectively, followed by a 5-min dissociation
phase. Concentrations for the three forms of RNA in the dilution series were
0.08–10 nM, 0.6–80 nM, and 2.5–160 nM, respectively.
To study the kinetics of RNA binding by RIG-CTD, dilution series of the three
different forms of RNA were injected in randomized duplicate runs at a flow
rate of 50 ml/min for 5 or 7 min, followed by a 3 or 4 min dissociation phase.
Concentrations for the three forms of RNA in the dilution series were 0.3–
5 nM, 0.6–10 nM, and 2.5–40 nM, respectively. Regeneration of the sensor
chip was achieved by injection of 10 mM glycine (at pH 2.2) at a flow rate of
20 ml/min for 210 s followed by HBS-EP+ buffer stabilization for 5 min. Sensor-
grams obtained from the SPR measurements were analyzed by the double-
subtraction method described by Myszka (1999). The signal from the reference
flow cell was subtracted from the analyte-binding response obtained from the
flow cell with captured ligand. Buffer reference responses were then averaged
from multiple injections. The averaged buffer reference response was then
subtracted from analyte-binding responses, and the final double-referenced
data were analyzed with BIAevaluation 3.0 (GE Healthcare). For the equilibrium
binding data, steady-state binding levels of the analytes were plotted against
analyte concentration, from which the equilibrium binding constant was esti-
mated. For the kinetic binding data, a one to one binding model was used to
globally fit the data to derive the association and dissociation rate constants.
Crystallization, Data Collection, and Structural Determination
The complex of RIG-I CTD with the 14-bp GC-rich dsRNA was concentrated to
about 30 mg/ml and crystallized in 18% PEG 3,350 in 0.1 M Bis-Tris buffer
(pH 5.5) containing 200 mM (NH4)2SO4 at 4
C. Large single crystals grew in
about one week. The complex of RIG-I CTD with the 12-bp AU-rich dsRNA
was crystallized under similar conditions in 0.1 M Bis-Tris buffer (pH 6.5).
The crystals were transferred stepwise into a cryoprotectant containing 30%
PEG 400 and were flash frozen in liquid nitrogen. Diffraction data were
collected using a Rigaku RAXIS IV++ detector mounted on a Rigaku Micro-
max-007HF generator. The diffraction data were processed with the
HKL2000 package (Otwinowski and Minor, 1997).
The complex of the 14-bp GC-rich dsRNA and RIG-I CTD crystallizes in
orthorhombic space group P212121 with the following cell dimensions:
a = 41.49 A˚, b = 96.87 A˚, and c = 103.40 A˚. The crystallographic asymmetric
unit (ASU) contains one 2:1 (RIG-CTD:dsRNA) complex. The 12-bp AU-rich
dsRNA complex crystallizes in hexagonal space group P65 with cell dimen-
sions as follows: a = b = 82.90 A˚, c = 111.16 A˚, and g = 120. There is one
2:1 (RIG-I CTD:dsRNA) complex in the ASU. The crystal is hemihedrally
twinned with a twin fraction of 0.478 with twinning operators h, -h-k, -l. The
twining fraction was determined using CNS (Brunger et al., 1998).
Structures of the RIG-I CTD in complex with the 14-bp and 12-bp dsRNA
were determined by molecular replacement with MOLREP in the CCP4 suite
(CCP4, 1994) using the crystal structure of RIG-I CTD in isolation as the search
model (PDB code: 2QFB, chain A). The structural models were rebuilt using O.
After several rounds of rebuilding and refinement with CNS, electron density
for the dsRNA became apparent. A 14 bp and a 12 bp dsRNA were manually
docked into the electron density map and rebuilt with O (Jones and Kjeldgaard,
1997). The structures were refined by several rounds of positional, simulated1043, August 11, 2010 ª2010 Elsevier Ltd All rights reserved 1041
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remodeling. The structure of RIG-I CTD bound to the 12-bp AU-rich dsRNA
was refined in CNS against the twinned data. A total of 20,357 reflections,
which correspond to 86% of a complete data set, were used in the structural
refinement. Only 5.5% of the diffraction data (1309 reflections) were rejected
because of twinning. Noncrystallographic symmetry (NCS) restraints were
not applied during the refinement because of the different crystal packing envi-
ronment of the RIG-I CTDs in the two complexes.
Mutagenesis of RIG-I CTD and RNA Binding Studies
Mutants of RIG-I CTD were generated using the Quikchange mutagenesis kit
(Stratagene). Sequences of the mutants were confirmed by plasmid DNA
sequencing. The mutant proteins were expressed and purified as described
above for the wild-type protein. For binding studies by EMSA, each type of
RNA was mixed with excess RIG-I CTD at a molar ratio of RNA to protein of
1:3 at a final concentration of 1.6:5 mM. The mixtures were separated on
12% nondenaturing polyacrylamide gel in 13 Tris-boric acid buffer without
EDTA. The gels were stained with ethidium bromide and were visualized using
Gel Doc XR (Bio-Rad). Binding studies for the mutants with the three different
forms of RNA were also performed by gel filtration chromatography. Each type
of RNA was mixed with excess RIG-I CTD at a molar ratio of RNA to protein of
1:3 (final concentration of about 12:36 mM) and 100 ml of samples were
analyzed on a Superdex200 (10/300 GL) column.
Mutagenesis of RIG-I and IFN-b Reporter Gene Assays
Mutations of full-length RIG-I were performed using pUNO-hRIG-I (Invivogen)
as template. Expression of wild-type and mutants of full-length RIG-I in the
transfected cells were confirmed by western blot using anti-RIG-I antibody
(C-15, sc-48929, Santa Cruz biotechnology). The luciferase assays used
actively growing HEK293T cells plated in CoStar White 96-well plates at 4.4
3 104 cells per well. When the cells were 80% confluent, they were trans-
fected with a mixture of Lipofectamine 2000 reagent (Invitrogen) and constant
amounts of the reporter plasmids IFN-b luc (30 ng per transfection; gift from Dr.
Rongtuan Lin, Lady Davis Institute for Medical Research, Montreal, QC,
Canada), phRL-TK (5 ng; Promega), and plasmids of wild-type and mutants
of human RIG-I pUNO-hRIG-I (0.5 ng; Invivogen). The cells were incubated
for 24 hr to allow expression from the plasmids. Different forms of RNA were
then transfected into the cells at a final concentration of 0.05 mM. After 16 hr
incubation, the cells were analyzed using the Dual-Glo Luciferase Assay
System reagents (Promega), quantifying luminescence with the BioTek
Synergy2 Plate Reader. The ratios of firefly luciferase over Renilla luciferase
were determined, and the ratio obtained with WT-RIG-I induced with RNA
was considered as 100% activity. The RNAs used in the assays were purified
either by preparative denaturing polyacrylamide gel electrophoresis or by gel
filtration chromatography.
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